NCT00440011已完成4 期
Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 266
- 主要终点
- Intraocular Pressure (IOP)
研究概览
简要总结
Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering, will be randomized to receive either bimatoprost 0.03% or travoprost 0.004% in place of latanoprost 0.005%
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Glaucoma or ocular hypertension in both eyes
- •Currently being treated with latanoprost 0.005% daily and in need of additional IOP-lowering
- •Best-corrected visual acuity of 20/100 or better in each eye
- •Visual field within 6 months of study entry
排除标准
- •Secondary glaucoma
- •Active intraocular inflammation or macular edema
- •Intraocular surgery or laser surgery within the past 3 months
研究组 & 干预措施
1
Experimental
干预措施: bimatoprost 0.03% eye drops (Drug)
2
Active Comparator
干预措施: travoprost 0.004% eye drops (Drug)
结局指标
主要结局
Intraocular Pressure (IOP)
时间窗: Month 3
Intraocular Pressure
次要结局
- Tolerability - Conjunctival Hyperemia(Month 3)
研究者
相似试验
已完成
4 期
Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%GlaucomaOcular HypertensionNCT00440141Allergan40
Unknown
不适用
Comparison of Bimatoprost and Latanoprost in Patients With Chronic Angle-Closure Glaucoma: A Randomized Cross-Over StudyGlaucoma, Angle-ClosureNCT00567788Singapore National Eye Centre60
已完成
4 期
A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular HypertensionGlaucoma, Open-AngleOcular HypertensionNCT02020512Allergan87
已完成
3 期
A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular HypertensionGlaucomaOcular HypertensionNCT01830140Allergan466
Unknown
不适用
Effects of Latanoprost, Bimatoprost and Travoprost in Patients With Latanoprost-resistant GlaucomaPrimary GlaucomaOcular HypertensionNCT01361841Centre de recherche du Centre hospitalier universitaire de Sherbrooke141